Table 2.

Univariate and multivariate analyses for prognostic factors of RFS.

Characteristics	Univariate analysis		Multivariate analysis
	HR (95% CI)	P	HR (95% CI)	P
Gender
Male (Ref)
Female	1.17 (0.52–2.59)	0.709
Age, years (continuous)	0.99 (0.96–1.02)	0.663
Functionality
Nonfunctional (Ref)
Functional	0.14 (0.02–1.02)	0.052
Tumor location
Head/neck (Ref)
Body/tail	2.00 (0.83–4.84)	0.122
Multiple parts	–	0.985
Tumor size, cm (continuous)	1.30 (1.14–1.48)	< 0.001		NS
Tumor focality
Single (Ref)
Multiple	0.93 (0.13–6.89)	0.942
Necrosis
No (Ref)
Yes	2.45 (0.58–10.4)	0.226
Nerve invasion
No (Ref)
Yes	5.44 (2.36–12.6)	< 0.001	3.63 (1.53–8.64)	0.003
Vascular invasion
No (Ref)
Yes	2.55 (1.06–6.17)	0.038		NS
Lymph node metastases
No (Ref)
Yes	3.02 (1.12–8.11)	0.029		NS
WHO grade
G1 (Ref)
G2	8.34 (1.90–36.5)	0.005	4.96 (1.09–22.6)	0.038
G3	39.9 (8.09–197)	< 0.001	15.1 (2.87–79.7)	0.001
TNM stage
I (Ref)
II	8.27 (1.08–63.6)	0.042		NS
III	16.6 (1.85–148)	0.012		NS
IV	88.4 (10.8–724)	< 0.001		NS
Synchronous liver metastases
No (Ref)
Yes	13.9 (5.67–34.0)	< 0.001	5.43 (2.17–13.6)	< 0.001
Platelet count, ×109/L (continuous)	1.00 (1.00–1.00)	0.241
Neutrophil count, ×109/L (continuous)	1.20 (0.85–1.69)	0.294
Lymphocyte count, ×109/L
≤1.4 (Ref)
>1.4	0.28 (0.12–0.65)	0.003		NS
Monocyte count, ×109/L (continuous)	12.7 (0.60–267)	0.103
PLR (continuous)	1.01 (1.00–1.01)	0.246
NLR
≤1.9 (Ref)
>1.9	2.26 (1.01–5.02)	0.046		NS
LMR
≤5.0 (Ref)
>5.0	0.21 (0.08–0.57)	0.002	0.30 (0.11–0.85)	0.023
SII index (continuous)	1.00 (1.00–1.00)	0.127

HR, hazard ratio; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-lymphocyte ratio; NS, not significant; PLR, platelet-to-lymphocyte ratio; Ref, reference; RFS, relapse-free survival; SII, systemic immune-inflammation; WHO, World Health Organization.